Ovarian Cancer Clinical Trial
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
This study looks at how well the Journey Ahead intervention works in improving coping and communication skills in participants with gynecologic cancers.
Primary goals of this project are:
Objective 1: Phase 1: To collect feedback from patients on CCI online and to assess patient's evaluation of CCI online.
Objective 2: Phase 1: To examine the feasibility and acceptability of a CCI online.
Objective 3: Phase 1/2: To collect preliminary data on changes in distress and coping associated with participation in CCI online.
Diagnosed with any stage of primary ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer or experienced a recurrence in the past 5 years;
Diagnosed with High Grade Stage 2, any grade Stage 3 or higher endometrial cancer or experienced a recurrence in the past 5 years;
Diagnosed with Stage 2 or higher cervical cancer or experienced a recurrence within the past 5 years;
Diagnosed with any stage Uterine Cancer (both Sarcoma and carcinosarcoma) or experienced a recurrence in the past 5 years;
At the time of recruitment the patient has received chemotherapy or radiation in the past 5 years, or is less than 5 years post-cancer surgery;
At the time of recruitment, a Karnofsky Performance Status of 80 or above or an Eastern Cooperative Oncology Group (ECOG) (80) score of 0 or 1;
18 years of age or older;
Has internet access, able to view the online intervention sessions and attend telephone or video/telehealth chats to discuss the session content and provide feedback;
Must give informed consent within 5 years of diagnosis.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New Brunswick New Jersey, 08901, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.